跳至主要内容
临床试验/JPRN-jRCTs071180093
JPRN-jRCTs071180093招募中2 期

Efficacy and safety of pyrimethamine/sulfadiazine/folinate combination therapy for the treatment of congenital toxoplasmosis - Treatment of congenital toxoplasmosis with pyrimethamine/sulfadiazine

Maruyama Haruhiko0 个研究点目标入组 35 人开始时间: 2019年3月29日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
35

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
All

入选标准

  • 1. Confirmed toxoplasmosis fulfilling one of the followings
  • #1 Toxoplasma DNA detected in placenta or other tissues
  • #2 pathological identification of Toxoplasma
  • #3 anti-Toxoplasma IgM in cord blood or sera within 6 months after birth
  • #4 increase of anti-Toxoplasma IgG within 1 year after birth
  • #5 positive anti-Toxoplasma IgG after 12 months after birth
  • 2. Suspected toxoplasmosis with all of the followings
  • #1 typical symptoms (e.g. intra-cranial calcification)
  • #2 positive anti-Toxoplasma IgG
  • #3 other congenital infections excluded

排除标准

  • #1 HIV positive patients
  • #2 patients allergic to test compounds
  • #3 patients with megaloblastic anemia due to
  • folate deficiency
  • #4 No consent is given from the patient
  • him/herself nor a legally authorized
  • representative/guardian of the patient
  • #5 patients principal investigator judged
  • inappropriate

研究者

发起方
Maruyama Haruhiko

相似试验